Cytokinetics

$15.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.77%) Today
+$0.06 (+0.39%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Cytokinetics and other stocks, options, and ETFs commission-free!

About CYTK

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Read More The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. The listed name for CYTK is Cytokinetics, Incorporated Common Stock.

CEO
Robert I. Blum
Employees
156
Headquarters
South San Francisco, California
Founded
1997
Market Cap
1.08B
Price-Earnings Ratio
Dividend Yield
Average Volume
838.84K
High Today
$15.49
Low Today
$14.91
Open Price
$15.49
Volume
713.36K
52 Week High
$30.14
52 Week Low
$7.73

Collections

CYTK Earnings

-$0.68
-$0.45
-$0.23
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
-$0.34 per share
Actual
Available Nov 4, After Hours

You May Also Like